Human CellExp™ VSIG4, human recombinant
V-set and immunoglobulin domain containing 4; Z39Ig; CRIg
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Y279 |
---|---|
Calculated MW | 68 kDa |
Gene ID | 11326 |
---|---|
Other Names | V-set and immunoglobulin domain containing 4; Z39Ig; CRIg |
Gene Source | Human |
Source | HEK 293 cells |
Assay&Purity | SDS-PAGE;≥ 98% |
Recombinant | Yes |
Target/Specificity | VSIG4 |
Application Notes | Reconstitute in 1X PBS to the desired protein concentration. |
Format | Lyophilized |
Storage | -20°C;Lyophilized from 0.2 µm-filtered solution in PBS. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
VSIG4 (V-set and immunoglobulin domain containing 4), as known as complement receptor of the immunoglobulin superfamily (CRIg) and Z39Ig. It is a B7 family-related protein and an Ig superfamily member. In contrast to the B7 family members which contain two IgG domains, VSIG4 contains one complete V-type I g domain and a truncated C-type I g domain. VSIG4 is exclusively expressed on tissue resident macrophages and binds to multimers of C3b and iC3b that are covalently attached to particle surfaces. VSIG4 functions as a negative regulator of T cell activation, and may be involved in the maintenance of peripheral T cell tolerance, and is also identified as a potent suppressor of established inflammation.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.